ASG Ribbon Logo Amyloidosis Patient Registry
Amyloidosis Support Groups
We are a phone call or email away!

ATTR Wild Type and Hereditary Amyloidosis

Explanation of Wild Type ATTR

ATTR-Wild Type and Hereditary Amyloidosis Support Group Meeting
October 27-29, 2023


ATTR Webinars - Videos On Demand

hATTR amyloidosis is a rare condition that occurs when an abnormal protein called amyloid builds up in tissue or organs like the heart, nervous system, and digestive tract. Watch our past online webinars on ATTR listed below. They are essentially a virtual patient education program that you can view on demand today (or at your convenience) and allows you to hear from doctors, advocates and people living with hATTR amyloidosis to learn about:

  • Understanding that amyloidosis can be a genetic condition
  • Determining with your doctor whether you or your loved one should seek genetic testing for hATTR amyloidosis
  • Communicating with family members the importance of genetic testing if a direct relative has already been diagnosed with a genetic form of amyloidosis

ASG ATTR Webinar, July 23, 2022

ASG ATTR Webinar, March 19, 2022

Moderator: Muriel Finkel, President, Amyloidosis Support Groups

Presenters and Panelists

Paula Schmitt, Executive Director, Amyloidosis Support Groups
Mathew S. Maurer, MD, Cardiologist, Director, Cardiac Amyloidosis Center, Professor of Medicine, Columbia University Medical Center
Nitasha Sarswat, MD, Director of Infiltrative Cardiomyopathy Program, University of Chicago Medicine
Lynn Punnoose, MD, Director, Vanderbilt Advanced Heart Failure/Transplant Fellowship Program, Vanderbilt University Medical Center
Sami Khella, MD, Chief of Neurology, Penn Presbyterian Medical Center
Michael Maitland, MD, PhD, Sr. Director, Clinical Development, Intellia Therapeutics
*Colleen Moffitt, PharmD, MS, US ATTR Medical Director, Alnylam Pharmaceuticals
Gustavo Buchele, MD, PhD, Executive Director, Clinical Development, Ionis Pharmaceuticals
*Abbas Ebrahim, MD, Sr. Medical Director, US Medical Affairs, Rare Disease, Pfizer
*Lori Baylor, PhD, Medical Director, Rare Cardiology, US Medical Affairs, Rare Disease, Pfizer
Spencer Guthrie, Cofounder & Chief Operating Officer, Attralus, Inc., South San Francisco, CA

*Presentations made by Alnylam and Pfizer during the webinar are not yet authorized for publication on YouTube. When and if authorized, ASG will make those presentations available on the YouTube channel.

Northeast ATTR Webinar, July 10, 2021


Welcome and Panelist Introductions, Muriel Finkel, ASG President
Transthyretin Cardiac Amyloidosis (ATTR-CM) Signs, Symptoms, and Diagnostic Approach, Farooq Sheikh, MD, FACC
Treatment for ATTR Cardiac Amyloid, John Berk, MD
Symptom Mangement in Cardiac Amyloidosis: Back to Basics, Frederick L. Ruberg, MD
Alnylam Clinical Trial Update, Gabriela Tamariz, MD
Eidos Clinical Trial Update, Makenna Paule
Ionis Clinical Trial Update, Gustavo Buchele, MD, PhD
Question and Answer Session 1, Panelists
Peripheral Neuropathy Symptoms, Diagnostic Tests, and Approved Treatments, Thomas Brannagan, MD
Symptom Management in Amyloid Neuropathy, Chafic Karam, MD
Alnylam Update on Clinical Trial for Hereditary TTR, Gabriela Tamariz, MD
Ionis Update on Clinical Trial for Hereditary TTR, Gustavo Buchele, MD, PhD
Intellia CRISPR CAS9 Update, Jeff Cehelsky, BS Pharm, MBA
Question and Answer Session 2, Panelists
Financial Assistance, Paula Schmitt, ASG Executive Director

Pacific Northwest ATTR Virtual Support Group Webinar, March 13, 2021


Introduction and Speaker Bios, Muriel Finkel, President, Amyloidosis Support Groups
Agenda, Dr. Ahmad Masri
ATTR in the Heart, Dr. Deirdre Mooney
Treatment for ATTR Cardiomyopathy, Dr. Richard Cheng
Amyloid Transthyretin (ATTR) Amyloidosis in the Nerves, Dr. Jane Distad
Amyloidosis — Why Did I Have to Get All of Those Tests? Dr. Edward Libby
ATTR Treatment: Navigating Through the Complexity of the Healthcare System, Dr. Hongya Chen
What do All These Neurological Tests Mean? Dr. Orly Moshe-Lilie
Transthyretin Amyloidosis: Advances and New Therapies, Dr. Ahmad Masri
Question and Answer Session, Panelists
Wrap Up and Final Thoughts, Panelists


Muriel Finkel, ASG President
Ahmad Masri, MD, MS, Cardiology, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University, Portland, OR
Deirdre Mooney, MD, MPH, FACC, Cardiologist at Sacred Heart Medical Center, Providence Health & Services, Spokane, WA
Richard Cheng, MD, MSc, Cardiologist/Cardio-oncologist, Assistant Professor of Cardiology, University of Washington, Seattle, WA
B. Jane Distad, MD, Director, EMG and Associate Professor, Department of Neurology, University of Washington, Seattle, WA
Orly Moshe-Lilie, MD, Neurologist, Neuromuscular Fellow at Oregon Health & Science University, Portland, OR
Edward N. Libby, MD, Hematology/Oncology, Associate Professor, Medical Oncology, University of Washington, Seattle, WA
Hongya Chen, PharmD, Cardiology, Oregon Health & Science University, Portland, OR

ATTR Treatments Amyloidosis Support Group Webinar, December 5, 2020


Introduction, Agenda plus Overview of TTR Amyloidosis - Muriel Finkel, President, ASG and Brett Sperry, MD
Ionis' Tegsedi Update plus Q&A on TTR Silencers - Gustavo Buchele, MD and Panelists
Pfizer's Vyndaqel and Vyndamax (tafamidis) - Adam Castano, MD
Corino's CRX-1008 - Michael Roberts, PhD
Q&A on TTR Stabilizers and Silencers - Panelists
ASG Update: Financial Assistance, oneAMYLOIDOSISvoice, Patient Registry - Paula Schmitt, ASG Executive Director
Intellia's CRISPR ATTR Treatment - Jeffrey Cehelsky, VP of Development Operations
ATTR Amyloid Imaging - Jonathan Wall, PhD
General Q&A Session 1 - Panelists
Clinical Trials Update* - Pfizer, Corino, Ionis, Intellia
General Q&A Session 2 - Panelists

*The webinar presentations and clinical trial updates by Alnylam about Onpattro (patisiran) and by Eidos about Acoramidis (AG10) are unavailable as they are not authorized for post-webinar distribution.

Speakers and Panelists

Brett Sperry, MD, St. Luke's Mid America Heart Institute and Assistant Professor of Medicine, University of Missouri, Kansas City, MO
Akshay Vaishnaw, MD, PhD, President, Research and Development, Alnylam Pharmaceuticals, Cambridge, MA
Steven Roblin, PhD, Medical Director, US TTR Lead, Alnylam Pharmaceuticals, Cambridge, MA
Gustavo Buchele, MD, PhD, Medical Director, Ionis Pharmaceutical, Inc., Carlsbad, CA
Adam Castano, MD, MS, Senior Medical Director, ATTR Cardiac Amyloidosis, Pfizer Inc., New York, NY
Alan Cohen, MD, Vice President, Global Medical Affairs, Eidos Therapeutics, Inc., San Francisco, CA
Michael Roberts, PhD, Chief Executive Officer, Corino Therapeutics, Inc., Charlotte, NC
Jeffrey Cehelsky, BS Pharm, MBA, Vice President of Development Operations, Intellia Therapeutics, Cambridge, MA
Jocelyn Ashford, Head of Global Patient Advocacy, Eidos Therapeutics, Inc., San Francisco, CA
Jonathan Wall, PhD, Professor, University of Tennessee Graduate School of Medicine, Knoxville, TN
Chafic Karam, MD, Associate Professor of Neurology, University of Pennsylvania, Philadelphia, PA
Nitasha Sarswat, MD, Director of Infiltrative Cardiomyopathy Program, University of Chicago, Chicago, IL

hATTR and ATTRwt Amyloidosis Support Group Meeting, August 15, 2020

Aug 15 2020 Webinar Playlist


Introduction, Memorial Tribute and Participant Bios - Muriel Finkel, President, ASG and Tracey Deutsch, International Liaison, ASG
Amyloidosis and the Heart - Martha Grogan, MD
Neurological Complications of ATTR Amyloidosis - Chafic Karam, MD
Amyloidosis and the Gut - John Clarke, MD
Health Insurance - Monica Bryant, Esq
Genetic Counseling for TTR Amyloidosis - Katie Agre, MS, LCGC
ASG Updates: Financial Assistance, oneAMYLOIDOSISvoice, Patient Registry- Paula Schmitt, ASG Executive Director and Bob Gibson, ASG Special Projects Director
Q&A Session - Speakers and Panelists


Martha Grogan, MD, Director, Cardiac Amyloid Clinic, Mayo Clinic, Rochester, MN
Chafic Karam, MD, Professor of Neurology, Oregon Health & Science University
John Clarke, MD, Director, Esophageal Program, Clinical Associate Professor of Medicine, Stanford University
Monica Bryant, Esq., Health Care Rights Attorney, Triage Cancer
Katie Agre, MS, Licensed Certified Genetic Counselor, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN


Kevin Alexander, MD, Assistant Professor of Medicine, The Stanford University Medical Center
Vincent Lau, MD, Assistant Professor of Neurology, Boston University School of Medicine, Boston, MA
Celestial Miller, MDA,RDN,CSO,CNSC,CD, University of Utah Healthcare, Salt Lake City, UT
Jignesh K. Patel, MD, PhD, Cedars-Sinai California Heart Center, Beverly Hills, CA
Maria M. Picken, MD, PhD, Professor, Loyola University Medical Center, Chicago, IL
Nitasha Sarswat, MD, Director of Infiltrative Cardiomyopathy Program, University of Chicago
Ron Witteles, MD, Co-Director, Stanford Amyloid Center, The Stanford University Medical Center

ATTR Amyloidosis Support Group Meeting, April 25, 2020

Apr 25 2020 ATTR Webinar Playlist


ATTR Cardiac Amyloidosis David Wolinsky, MD, Director Cardiac Amyloid Clinic, Cleveland Clinic, Florida
Peripheral and Autonomic Neuropathy Chafic Karam, MD, Professor of Neurology, Oregon Health & Science University
Renal Amyloidosis Andrea Havasi, MD, Amyloidosis Center, Boston University School of Medicine
Imaging Systemic Amyloidosis (ATTR) Johnathan Wall, MD, University of Tennessee Graduate School of Medicine
Questions and Answers, Panelists

For information on earlier events before 2020, visit our deep archives page.

ATTR Treatments Currently FDA Approved

ATTR (Hereditary with PN)
Alnylam's Onpattro (Patisiran) Click Here
Akcea's Tegsedi (Inotersen) Click Here
ATTR (Hereditary and WT with CM )
Pfizer's Vyndamax Click Here
Free Genetic Counseling and Testing

Akcea Compass

Alnylam Act

Financial Assistance

The Assistance Fund Opens New Program for Hereditary (ATTR) Amyloidosis

Patient Help Network

Do you want your family to know about hereditary ATTR amyloidosis?

Inform them using this pre-written letter: Click Here for Family Letter (PDF)